Reportlinker Adds Antifungals Market to 2016 - Promising Antifungals in Pipeline Includes Novel Azoles, Polyenes and Echinocandin

Mar 31, 2011, 09:53 ET from Reportlinker

NEW YORK, March 31, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Antifungals Market to 2016 - Promising Antifungals in Pipeline Includes Novel Azoles, Polyenes and Echinocandin

http://www.reportlinker.com/p0397056/Antifungals-Market-to-2016---Promising-Antifungals-in-Pipeline-Includes-Novel-Azoles-Polyenes-and-Echinocandin.html

Antifungals Market to 2016 - Promising Antifungals in Pipeline Includes Novel Azoles, Polyenes and Echinocandin

Summary

GBI Research, a leading business intelligence provider, has released its latest research "Antifungals Market to 2016 - Promising Antifungals in Pipeline Includes Novel Azoles, Polyenes and Echinocandin", which provides insights into antifungals sales and price forecasts until 2016. The report examines global treatment usage patterns of antifungals therapies. The geographical distribution of antifungals therapies across the US, the top five countries in the European region and Japan are also provided in the report. The report includes insights into the antifungals R&D pipeline and potential future blockbusters up to 2016. The report provides an in-depth analysis of the top three antifungals therapeutic indications, which are aspergillosis, dermatophytosis and candidiasis. It also includes the market forecasts and treatment usage patterns of these three therapeutic indications. The report explores the competitive landscape including top companies benchmarking, and the key trend analysis on Mergers and Acquisitions (M&A) and licensing agreements involving antifungals therapies are also presented. In-depth analysis of the report is based on propriety databases, primary and secondary research and in-house analysis by GBI Research's team of experts. GBI Research's analysis showed that the global antifungals market was estimated at $7.4 billion in 2009, with a year-on-year growth rate of 2.3% between 2001 and 2009. The antifungals market is dominated by target therapeutics, which is more efficient and safe when compared to other conventional therapies. GBI Research forecasts that the market will grow at a Compound Annual Growth Rate (CAGR) of 1.9% between 2009 and 2016 to record a sales value of $8.4 billion. The patent expiry of the major drugs has also paved the way for the entry of generics.

Scope

The scope of this report includes -

- Annualized market data for the antifungals market from 2001 to 2009, with forecasts to 2016.

- Market analysis for the three major indications in the global antifungals market which includes Aspergillosis, Dermatophytosis and Candidiasis.

- Data and analysis on the antifungals market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.

- Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.

- The competitive landscape of the global antifungals market including SWOT analysis

- Key M&A activities and licensing agreements that took place in 2008 and 2009 in the antifungals market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Build effective strategies to launch their pipeline products by identifying potential geographies.

- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.

- Develop key strategic initiatives by studying the key strategies of top competitors.

- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.

- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious..

Table of Contents

1 Table of Contents

1 Table of Contents 3

1.1 List of Tables 6

1.2 List of Figures 8

2 Global Antifungals Market: Introduction 10

2.1 Overview 10

2.2 GBI Research Report Guidance 10

3 Global Antifungals Market: Market Characterization 11

3.1 Introduction 11

3.2 Forecast for Global Antifungals Market 11

3.2.1 Revenues 11

3.2.2 Annual Cost of Treatment (ACT) 12

3.2.3 Treatment Usage Patterns 13

3.3 Drivers for the Antifungals Market 18

3.3.1 Large Patients Population 18

3.3.2 Diagnosis Rate 18

3.4 Barriers for the Antifungals Market 18

3.4.1 Prominence of Generics in the Market 18

4 Global Antifungals Market: Geographical landscape 19

4.1 Revenue Analysis by Geography 19

4.2 The US 19

4.2.1 Revenue 19

4.2.2 Annual Cost of Treatment 20

4.2.3 Treatment Usage Pattern 21

4.3 Top Five Countries of Europe 26

4.3.1 Revenue 26

4.3.2 Annual Cost of Treatment 27

4.3.3 Treatment Usage Pattern 28

4.4 Japan 33

4.4.1 Revenue 33

4.4.2 Annual Cost of Treatment 34

4.4.3 Treatment Usage Pattern 35

5 Global Antifungals Market : Aspergillosis Therapeutics Market 40

5.1 Introduction 40

5.2 Market Forecasts 40

5.3 Annual Cost of Treatment 41

5.3.1 Annual Cost of Treatment for Allergic Bronchopulmonary Aspergillosis 41

5.3.2 Annual Cost of Treatment for Invasive aspergillosis 42

5.4 Treatment Usage Patterns 43

5.4.1 Diseased Population 44

5.4.2 Treatment Seeking Population 45

5.4.3 Diagnosed Population 46

5.4.4 Prescription Population 47

5.5 Major Marketed Products 47

5.5.1 Voriconazole (Vfend) 47

5.5.2 Amphotericin B(Amphocin) 48

5.5.3 Itraconazole (Sporanox) 48

5.5.4 Caspofungin (Cancidas) 48

5.5.5 Posconazole (Noxafil) 49

5.5.6 Prednisone (Deltasone) 49

6 Global Antifungals Market : Dermatophytosis Therapeutics Market 50

6.1 Introduction 50

6.2 Market Forecasts 50

6.3 Annual Cost of Treatment 51

6.3.1 Annual Cost of Treatment for Tinea Cruris 51

6.3.2 Annual Cost of Treatment for Tinea Unguium (Onychomycosis) 52

6.3.3 Annual Cost of Treatment for Tinea Pedis 53

6.3.4 Annual Cost of Treatment for Tinea Capitis 54

6.3.5 Annual Cost of Treatment for Tinea Corporis 55

6.4 Treatment Usage Patterns 56

6.4.1 Diseased Population 57

6.4.2 Treatment Seeking Population 58

6.4.3 Diagnosed Population 59

6.4.4 Prescription Population 60

6.5 Major Marketed Products 60

6.5.1 Ketoconazole 2% cream (Nizoral) 60

6.5.2 Clotrimazole 1% cream or lotion (Lotrimin) 61

6.5.3 Econazole 1% cream or lotion (Spectazole) 61

6.5.4 Miconazole 2% cream (Monistat) 61

6.5.5 Terbinafine (Lamisil) 61

6.5.6 Naftifine 1% cream (Naftifin) 62

6.5.7 Griseofulvin 62

6.5.8 Itraconazole (Sporanox) 62

6.5.9 Fluconazole (Diflucan) 62

6.5.10 Sertaconazole nitrate cream (Ertaczo) 63

7 Global Antifungals Market : Candidiasis Therapeutics Market 64

7.1 Introduction 64

7.2 Market Forecasts 64

7.3 Annual Cost of Treatment 65

7.3.1 Annual Cost of Treatment for Vaginal Candidiasis 65

7.3.2 Annual Cost of Treatment for Cutaneous Candidiasis 66

7.3.3 Annual Cost of Treatment for Oropharyngeal Candidiasis 67

7.3.4 Annual Cost of Treatment for Esophageal Candidiasis 68

7.3.5 Annual Cost of Treatment for Invasive Candidiasis 69

7.4 Treatment Usage Patterns 70

7.4.1 Diseased Population 71

7.4.2 Treatment Seeking Population 72

7.4.3 Diagnosed Population 73

7.4.4 Prescription Population 74

7.5 Major Marketed Products 74

7.5.1 Fluconazole 74

7.5.2 Itraconazole (Oral Solution) 75

7.5.3 Clotrimazole 75

7.5.4 Anidulafungin (Eraxis) 75

7.5.5 Nystatin (Oral Suspension) 75

8 Global Antifungals Market: Pipeline Analysis 76

8.1 Introduction 76

8.2 Aspergillosis: Research and Development Pipeline 77

8.2.1 Overview 77

8.2.2 Pipeline by Clinical Phases of Development 77

8.3 Dermatophytosis: Research and Development Pipeline 79

8.3.1 Overview 79

8.3.2 Pipeline by Clinical Phases of Development 79

8.4 Candidiasis: Research and Development Pipeline 81

8.4.1 Overview 81

8.4.2 Pipeline by Clinical Phases of Development 81

8.5 Profiles of Promising Drugs in the Antifungals Market 82

8.5.1 Eraxis + Vfend 82

8.5.2 Isavuconazole 83

8.5.3 NAFT-500 83

8.5.4 Fluconazole 84

8.5.5 Lavender Vaginal Cream 84

9 Global Antifungals Market: Competitive Landscape 85

9.1 Company Profiles for Antifungals 85

9.1.1 Ferrer Internacional S.A. 85

9.1.2 BioDelivery Sciences International, Inc. 86

9.1.3 Basilea Pharmaceutica Ltd. 87

9.1.4 Almirall, S.A. 88

9.1.5 Pfizer Inc. 89

9.1.6 Sigma-Tau S.p.A. 90

9.1.7 Piramal Life Sciences Limited 91

10 Global Antifungals Market: Strategic Consolidations 93

10.1 Mergers and Acquisitions 93

10.1.1 Overview 93

10.1.2 Major Mergers and Acquisitions Deals 93

10.1.3 Segmentation by Geography 94

10.1.4 Segmentation by Deal Value 95

10.1.5 Segmentation by Year 96

10.2 Co-development Deals 96

10.2.1 Overview 96

10.2.2 Major Co-development Deals 96

10.2.3 Segmentation by Geography 97

10.2.4 Segmentation by Year 98

10.3 Licensing Deals 98

10.3.1 Overview 98

10.3.2 Major Licensing Deals 98

10.3.3 Segmentation by Geography 99

10.3.4 Segmentation by Value 100

11 Global Antifungals Market : Appendix 101

11.1 Market Definitions 101

11.2 Abbreviations 101

11.3 Research Methodology 102

11.3.1 Coverage 102

11.3.2 Primary Research 102

11.3.3 Forecasts 103

11.3.4 Expert Panel Validation 106

11.4 Contact Us 106

11.5 Disclaimer 106

11.6 Sources 106

List of Tables

1.1 List of Tables

Table 1: Antifungals Market, Global, Revenues ($bn), 2001-2009 11

Table 2: Antifungals Market, Global, Revenues ($bn), 2009-2016 11

Table 3: Antifungals Market, Global, Annual Cost of Treatment ($), 2001-2009 12

Table 4: Antifungals Market, Global, Annual Cost of Treatment ($), 2009-2016 12

Table 5: Antifungals Market, Global, Treatment Usage Patterns, (millions), 2001-2009 13

Table 6: Antifungals Market, Global, Treatment Usage Patterns, (millions), 2009-2016 14

Table 7: Antifungals Market, The US, Revenues ($bn), 2001-2009 19

Table 8: Antifungals Market, The US, Revenues ($bn), 2009-2016 19

Table 9: Antifungals Market, The US, Annual Cost of Treatment ($), 2001-2009 20

Table 10: Antifungals Market, The US, Annual Cost of Treatment ($), 2009-2016 20

Table 11: Antifungals Market, The US, Treatment Usage Patterns (millions), 2001-2009 21

Table 12: Antifungals Market, The US, Treatment Usage Patterns (millions), 2009-2016 22

Table 13: Antifungals Market, Top Five Countries of Europe, Revenues ($bn), 2001-2009 26

Table 14: Antifungals Market, Top Five Countries of Europe, Revenues ($bn), 2009-2016 26

Table 15: Antifungals Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2001-2009 27

Table 16: Antifungals Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2009-2016 27

Table 17: Antifungals Market, Top Five Countries of Europe, Treatment Usage Patterns (millions), 2001-2009 28

Table 18: Antifungals Market, Top Five Countries of Europe, Treatment Usage Patterns (millions), 2009-2016 29

Table 19: Antifungals Market, Japan, Revenues ($bn), 2001-2009 33

Table 20: Antifungals Market, Japan, Revenues ($bn), 2009-2016 33

Table 21: Antifungals Market, Japan, Annual Cost of Treatment ($), 2001-2009 34

Table 22: Antifungals Market, Japan, Annual Cost of Treatment ($), 2009-2016 34

Table 23: Antifungals Market, Japan, Treatment Usage Patterns, (millions), 2001-2009 35

Table 24: Antifungals Market, Japan, Treatment Usage Patterns, (millions), 2009-2016 36

Table 25: Aspergillosis Therapeutics Market, Global, Revenues ($m), 2001-2009 40

Table 26: Aspergillosis Therapeutics Market, Global, Revenues ($m), 2009-2016 40

Table 27: Aspergillosis Therapeutics Market, Global, Annual Cost of Treatment, Allergic Bronchopulmonary Aspergillosis ($), 2001-2009 41

Table 28: Aspergillosis Therapeutics Market, Global, Annual Cost of Treatment, Allergic Bronchopulmonary Aspergillosis ($), 2009-2016 41

Table 29: Aspergillosis Therapeutics Market, Global, Annual Cost of Treatment, Invasive Aspergillosis ($), 2001-2009 42

Table 30: Aspergillosis Therapeutics Market, Global, Annual Cost of Treatment, Invasive Aspergillosis ($), 2009-2016 42

Table 31: Aspergillosis Therapeutics Market, Global, Treatment Usage Pattern ('000), 2001-2009 43

Table 32: Aspergillosis Therapeutics Market, Global, Treatment Usage Pattern ('000), 2009-2016 43

Table 33: Dermatophytosis Therapeutics Market, Global, Revenues ($bn), 2001-2009 50

Table 34: Dermatophytosis Therapeutics Market, Global, Revenues ($bn), 2009-2016 50

Table 35: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Cruris ($), 2001-2009 51

Table 36: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Cruris ($), 2009-2016 51

Table 37: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Unguium ($), 2001-2009 52

Table 38: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Unguium ($), 2009-2016 52

Table 39: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Pedis ($), 2001-2009 53

Table 40: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Pedis ($), 2009-2016 53

Table 41: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Capitis ($), 2001-2009 54

Table 42: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Capitis ($), 2009-2016 54

Table 43: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Corporis ($), 2001-2009 55

Table 44: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Corporis ($), 2009-2016 55

Table 45: Dermatophytosis Therapeutics Market, Global, Treatment Usage Patterns, (millions), 2001-2009 56

Table 46: Dermatophytosis Therapeutics Market, Global, Treatment Usage Patterns, (millions), 2009-2016 57

Table 47: Candidiasis Therapeutics Market, Global, Revenues ($), 2001-2009 64

Table 48: Candidiasis Therapeutics Market, Global, Revenues ($), 2009-2016 64

Table 49: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Vaginal Candidiasis ($), 2001-2009 65

Table 50: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Vaginal Candidiasis ($), 2009-2016 65

Table 51: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Cutaneous Candidiasis ($), 2001-2009 66

Table 52: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Cutaneous Candidiasis ($), 2009-2016 66

Table 53: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Oropharyngeal Candidiasis ($), 2001-2009 67

Table 54: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Oropharyngeal Candidiasis ($), 2009-2016 67

Table 55: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Esophageal Candidiasis ($), 2001-2009 68

Table 56: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Esophageal Candidiasis ($), 2009-2016 68

Table 57: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Invasive Candidiasis ($), 2001-2009 69

Table 58: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Invasive Candidiasis ($), 2009-2016 69

Table 59: Candidiasis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2001-2009 70

Table 60: Candidiasis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2009-2016 71

Table 61: Antifungals Market, Aspergillosis Pipeline, Global, Number of Preclinical Molecules, 2010 77

Table 62: Antifungals Market, Aspergillosis Pipeline, Global, Number of Phase l Molecules, 2010 77

Table 63: Antifungals Market, Aspergillosis Pipeline, Global, Number of Phase ll Molecules, 2010 78

Table 64: Antifungals Market, Aspergillosis Pipeline, Global, Number of Phase lll Molecules, 2010 78

Table 65: Antifungals Market, Dermatophytosis Pipeline, Global, Number of Preclinical Molecules, 2010 79

Table 66: Antifungals Market, Dermatophytosis Pipeline, Global, Number of Phase l Molecules, 2010 79

Table 67: Antifungals Market, Dermatophytosis Pipeline, Global, Number of Phase ll Molecules, 2010 80

Table 68: Antifungals Market, Dermatophytosis Pipeline, Global, Number of Phase lll Molecules, 2010 80

Table 69: Antifungals Market, Candidiasis Pipeline, Global, Number of Preclinical Molecules, 2010 81

Table 70: Antifungals Market, Candidiasis Pipeline, Global, Number of Phase l Molecules, 2010 81

Table 71: Antifungals Market, Candidiasis Pipeline, Global, Number of Phase ll Molecules, 2010 82

Table 72: Antifungals Market, Candidiasis Pipeline, Global, Number of Phase lll Molecules, 2010 82

List of Figures

1.2 List of Figures

Figure 1: Antifungals Market, Global, Revenues ($bn), 2001-2016 11

Figure 2: Antifungals Market, Global, Annual Cost of Treatment ($), 2001-2016 12

Figure 3: Antifungals Market, Global, Treatment Usage Patterns, (millions), 2001-2016 13

Figure 4: Antifungals Market, Global, Diseased Population (millions), 2001-2016 14

Figure 5: Antifungals Market, Global, Treatment Seeking Population (millions), 2001-2016 15

Figure 6: Antifungals Market, Global, Diagnosed Population (millions), 2001-2016 16

Figure 7: Antifungals Market, Global, Prescription Population (millions), 2001-2016 17

Figure 8: Antifungals Market, The US, Revenues ($bn), 2001-2016 19

Figure 9: Antifungals Market, The US, Annual Cost of Treatment ($), 2001-2016 20

Figure 10: Antifungals Market, The US, Treatment Usage Patterns (millions), 2001-2016 21

Figure 11: Antifungals Market, The US, Diseased Population (millions), 2001-2016 22

Figure 12: Antifungals Market, The US, Treatment Seeking Population (millions), 2001-2016 23

Figure 13: Antifungals Market, The US, Diagnosed Population (millions), 2001-2016 24

Figure 14: Antifungals Market, The US, Prescription Population (millions), 2001-2016 25

Figure 15: Antifungals Market, Top Five Countries of Europe, Revenues ($bn), 2001-2016 26

Figure 16: Antifungals Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2001-2016 27

Figure 17: Antifungals Market, Top Five Countries of Europe, Treatment Usage Patterns (millions), 2001-2016 28

Figure 18: Antifungals Market, Top Five Countries of Europe, Diseased Population (millions), 2001-2016 29

Figure 19: Antifungals Market, Top Five Countries of Europe, Treatment Seeking Population (millions), 2001-2016 30

Figure 20: Antifungals Market, Top Five Countries of Europe, Diagnosed Population (millions), 2001-2016 31

Figure 21: Antifungals Market, Top Five Countries of Europe, Prescription Population (millions), 2001-2016 32

Figure 22: Antifungals Market, Japan, Revenues ($bn), 2001-2016 33

Figure 23: Antifungals Market, Japan, Annual Cost of Treatment ($), 2001-2016 34

Figure 24: Antifungals Market, Japan, Treatment Usage Patterns, (millions), 2001-2016 35

Figure 25: Antifungals Market, Japan, Diseased Population (millions), 2001-2016 36

Figure 26: Antifungals Market, Japan, Treatment Seeking Population (millions), 2001-2016 37

Figure 27: Antifungals Market, Japan, Diagnosed Population (millions), 2001-2016 38

Figure 28: Antifungals Market, Japan, Prescription Population (millions), 2001-2016 39

Figure 29: Aspergillosis Therapeutics Market, Global, Revenues ($m), 2001-2016 40

Figure 30: Aspergillosis Therapeutics Market, Global, Annual Cost of Treatment, Allergic Bronchopulmonary Aspergillosis ($), 2001-2016 41

Figure 31: Aspergillosis Therapeutics Market, Global, Annual Cost of Treatment, Invasive Aspergillosis ($), 2001-2016 42

Figure 32: Aspergillosis Therapeutics Market, Global, Treatment Usage Pattern ('000), 2001-2016 43

Figure 33: Aspergillosis Therapeutics Market, Global, Diseased Population ('000), 2001-2016 44

Figure 34: Aspergillosis Therapeutics Market, Global, Treatment Seeking Population ('000), 2001-2016 45

Figure 35: Aspergillosis Therapeutics Market, Global, Diagnosed Population ('000), 2001-2016 46

Figure 36: Aspergillosis Therapeutics Market, Global, Prescription Population ('000), 2001-2016 47

Figure 37: Dermatophytosis Therapeutics Market, Global, Revenues ($bn), 2001-2016 50

Figure 38: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Cruris ($), 2001-2016 51

Figure 39: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Unguium ($), 2001-2016 52

Figure 40: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Pedis ($), 2001-2016 53

Figure 41: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Capitis ($), 2001-2016 54

Figure 42: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Corporis ($), 2001-2016 55

Figure 43: Dermatophytosis Therapeutics Market, Global, Treatment Usage Patterns, (millions), 2001-2016 56

Figure 44: Dermatophytosis Therapeutics Market, Global, Diseased Population (millions), 2001-2016 57

Figure 45: Dermatophytosis Therapeutics Market, Global, Treatment Seeking Population (millions), 2001-2016 58

Figure 46: Dermatophytosis Therapeutics Market, Global, Diagnosed Population (millions), 2001-2016 59

Figure 47: Dermatophytosis Therapeutics Market, Global, Prescription Population (millions), 2001-2016 60

Figure 48: Candidiasis Therapeutics Market, Global, Revenues ($), 2001-2016 64

Figure 49: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Vaginal Candidiasis ($), 2001-2016 65

Figure 50: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Cutaneous Candidiasis ($), 2001-2016 66

Figure 51: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Oropharyngeal Candidiasis ($), 2001-2016 67

Figure 52: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Esophageal Candidiasis ($), 2001-2016 68

Figure 53: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Invasive Candidiasis ($), 2001-2016 69

Figure 54: Candidiasis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2001-2009 70

Figure 55: Candidiasis Therapeutics Market, Global, Diseased Population (millions), 2001-2016 71

Figure 56: Candidiasis Therapeutics Market, Global, Treatment Seeking Population (millions), 2001-2016 72

Figure 57: Candidiasis Therapeutics Market, Global, Diagnosed Population (millions), 2001-2016 73

Figure 58: Candidiasis Therapeutics Market, Global, Prescription Population (millions), 2001-2016 74

Figure 59: Antifungals Market, Global, Number of Molecules by Indication (%), 2001-2010 76

Figure 60: Antifungals Market, Aspergillosis Pipeline, Global, Number of Molecules by Stages (%), 2010 77

Figure 61: Antifungals Market, Dermatophytosis Pipeline, Global, Number of Molecules by Stages (%), 2010 79

Figure 62: Antifungals Market, Candidiasis Pipeline, Global, Number of Molecules by Stages (%), 2010 81

Figure 63: Antifungals Market, SWOT Analysis - Ferrer Internacional SA 85

Figure 64: Antifungals Market, SWOT Analysis - BioDelivery Sciences International Inc 87

Figure 65: Antifungals Market, SWOT Analysis - Basilea Pharmaceutica ltd 88

Figure 66: Antifungals Market, SWOT Analysis - Almirall SA 89

Figure 67: Antifungals Market, SWOT Analysis - Pfizer Inc 90

Figure 68: Antifungals Market, SWOT Analysis - Sigma Tau 91

Figure 69: Antifungals Market, SWOT Analysis - Piramal Lifesciences Ltd 92

Figure 70: Antifungals Market, Global, Number of M&A Deals (%), 2004-2010 94

Figure 71: Antifungals Market, Global, Value of M&A Deals ($m), 2004-2010 95

Figure 72: Antifungals Market, Global, Number of M&A Deals Yearly (%), 2004-2010 96

Figure 73: Antifungals Market, Global, Number of Co-Development Deals by Geography (%), 2004-2010 97

Figure 74: Antifungals Market, Global, Number of Co-Development Deals (%), 2004-2010 98

Figure 75: Antifungals Market, Global, Number of licensing Deals (%), 2004-2010 99

Figure 76: Antifungals Market, Global, Value of Licensing Deals ($m), 2004-2010 100

Figure 77: GBI Research Market Forecasting Model 105

To order this report: Antifungals Market to 2016 - Promising Antifungals in Pipeline Includes Novel Azoles, Polyenes and Echinocandin

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com